East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
eResearchTechnology Signs $6 Million Franchise Agreement for
Cardiac Safety Monitoring and Distribution Services
Agreement Delivers Capacity and Compliance for Multi-National Drug Developer,
Mitigating Risks Associated with Industry Capacity Constraints
PHILADELPHIA, June 24 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has
entered into an agreement with a total value of about $6 million over two years
with a multi-national drug developer to provide comprehensive cardiac safety
and related services for compounds in all phases of clinical development.
eRT will leverage its Digital ECG Franchise program to deliver core laboratory
services associated with this agreement. The Digital ECG Franchise program
offers a unique approach designed to address the growing capacity demands for
eRT's ECG services through partnerships with sponsors that desire dedicated
resources within eRT to address specific levels of cardiac safety monitoring
transactions.
"eRT's latest Franchise agreement is built on the foundation of a strong
partnership in the clinical pharmacology area with this significant multi-
national pharmaceutical organization and extends collaboration across all
phases of clinical development," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT. "This Franchise
demonstrates continued momentum in demand for cardiac safety services for new
drug developers that have elected to secure dedicated resources to mitigate
risks associated with potential industry capacity constraints. The agreement
includes built-in provisions to flexibly expand capacity beyond the $6 million
commitment level as required by the sponsor's clinical development programs.
Also, the agreement further validates eRT's unique Franchise strategy, which
provides sponsors with dedicated resources that ensure capacity, quality, and
cost effectiveness."
eRT will perform digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT(R) workflow enabled data
handling technology, the first solution in production that was designed
explicitly to meet emerging international regulatory guidance and technical
standards.
In addition to a significant number of ECG transactions and built-in expansion
capabilities, the Franchise program includes a variety of related services:
-- Allocation of standing 12-lead ECG units and continuous 12-lead ECG
recording devices directly to the sponsor's selected sites for each
trial.
-- Project Assurance services to address key operational requirements
such as project management, site support, and a 24x7 Global Customer
Care Call Center.
-- Access to eRT's Digital ECG Community, which delivers timely cardiac
safety data feedback at the trial, center, and patient level, along
with related metrics, such as trial enrollment, as well as the ability
to organize and publish a variety of study-specific information and
the ability to link data points in a report direct to digital ECG
waveforms.
-- Powerful eReporting capabilities designed to provide information
critical to collaboration between sponsors, research sites, and eRT to
attain mastery in the digital age. eReporting can be delivered
automatically via fax or via eRT's eReporting Bulletin Board - a
sponsor, program, and trial specific secure Web site.
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsor may cancel this agreement at its discretion. As a result,
actual results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the company's
financial results can be found in the company's Reports on Forms 10-K and 10-Q
filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or
Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology
Web site: http://www.ert.com/